{"id":47350,"date":"2017-07-05T10:46:20","date_gmt":"2017-07-05T14:46:20","guid":{"rendered":"https:\/\/asweetlife.org\/?p=47350"},"modified":"2017-07-05T13:07:08","modified_gmt":"2017-07-05T17:07:08","slug":"studies-show-diabetes-drug-invokana-increases-amputation-risk","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=47350","title":{"rendered":"Studies Show Diabetes Drug Invokana Increases Amputation Risk"},"content":{"rendered":"

People with diabetes who take a class of drugs known as sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors will now need to weigh benefits against risks after studies showed the medications significantly reduce heart problems in subjects, but, surprisingly, also increase the risk of amputation.<\/p>\n

The results of the studies<\/a> on the Johnson & Johnson drug canagliflozin, marketed under the name Invokana<\/a>, confirm cardiovascular benefits not only for that particular medication, but also for others in its class. Those same results, however, call into question whether other drugs in the class also contribute to increased amputation.<\/p>\n

\u201cDrugs to treat diabetes have been undergoing a positive transformation in the last three or four years,\u201d says Dr. Bruce Neal<\/a>, lead investigator in the study and professor of medicine for University of New South Wales Sydney, and senior director, the George Institute for Global Health<\/a> in Sydney, Australia. \u201cIt used to be we would test diabetes drugs to see if they lowered glucose levels and did not cause heart problems. Now, we test drugs and expect to see them not only lower glucose but improve cardiovascular health. It\u2019s been extraordinary. But, now we might be finding out that there are glitches along the way.\u201d<\/p>\n

Neal led a team of six other academic researchers combining data from two studies, the first a clinical trial before the drug was approved by the Food and Drug Administration in 2013 and the second a post-marketing study designed to detect any cardiovascular risks from the drug. Such studies are a recent requirement of the FDA to ensure safety of new medications across a wider population than may have been tested in clinical trials for the drug\u2019s initial approval.<\/p>\n

The studies, one called Canagliflozin Cardiovascular Assessment Study<\/a> or CANVAS, and the second CANVAS-R, looked at 10,142 type 2 diabetics, all of whom had high cardiovascular risk. The data revealed that Invokana not only reduced cardiac problems in people with type 2 diabetes but it did so significantly while also reducing kidney problems by an even bigger margin.<\/p>\n

\u201cThe good news is that the data shows the drug reduced major cardiovascular adverse events by twenty three per 1,000 subjects over five years,\u201d Neal says. \u201cIt reduced the chance of hospitalization for heart failure by seventeen subjects, and major renal events by sixteen subjects. These are very impressive numbers.\u201d<\/p>\n

The numbers are more impressive when they are conjoined with results from other research into the same kind of drug as Invokana, which is a sodium\u2013glucose cotransporter 2 (SGLT2) inhibitor. Clinical trails on a drug from Boehringer Ingleheim\/Lilly called empafloglozin and marketed under the name Jardiance<\/a> showed similar cardiovascular and renal benefits to users, as did the only other drug in the class, dapagliflozin, marketed as Farxiga<\/a>, from Astra Zenega Pharmaceuticals.<\/p>\n

Neal says results of studies on the entire class of drugs suggests strongly that the entire class carries cardiovascular and renal benefits. He says that the cardiovascular and renal benefits in those drugs are not because of one ingredient in each. Rather, it appears that the overall mechanism of the drug\u2019s joint effects on multiple factors including blood glucose, blood pressure, and kidney protection is what contributes to the benefits.<\/p>\n

According to the European Medicines Agency<\/a> (EMA) the medications act to \u201cblock a protein in the kidneys called SGLT2, which absorbs glucose back from the urine into the bloodstream as the blood is filtered in the kidneys. By blocking the action of SGLT2, these medicines cause more glucose to be lost in the urine, thereby reducing the levels of glucose in the blood.\u201d<\/p>\n

Neal says this action not only reduces cardiovascular and kidney problems, but also works to address the possibility of stroke.<\/p>\n

The problem of amputations, however, as shown in the results of testing on Invokana, remains.<\/p>\n

The data shows that amputations of the toes and forefoot\u2014and fewer above the ankle\u2014occurred about twice as often in subjects taking Invokana than taking placebo.<\/p>\n

\u201cIt is unclear at the moment what the cause of the amputation is,\u201d Neal says. \u201cThis is clearly a side effect we don\u2019t want.\u201d<\/p>\n

He said more data collection, and perhaps additional clinical trials will be conducted, to determine if the increased amputation risk is the same for the entire class of drugs or not. \u201cWe\u2019re only at the start of this process,\u201d Neal says. \u201cThere will be more study and more papers to try and figure out what is taking place.\u201d<\/p>\n

When asked how to proceed with taking the drug because of this news Neal, who stresses that he is an academic researcher and not a regulator, says he would follow the advice of regulators.<\/p>\n

That advice from the FDA<\/a> has been to put a boxed warning on Invokana advising users of the drug that there is an increased amputation risk. In Europe, such warnings are on the entire class of drugs. Additionally, Invokana already includes warnings regarding increased chances of acute kidney injury and urinary tract infections from the drug.<\/p>\n

Neal says if patients are concerned the best person to speak to is their doctor.<\/p>\n

\u201cDoctors don\u2019t treat 1,000 people,\u201d he says. \u201cThey treat 1,000 individual patients. Each person is different and needs to weigh all the factors that might affect them in deciding whether or not to use a medication.\u201d<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

…<\/p>\n","protected":false},"author":4,"featured_media":37306,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1542,1442],"tags":[1291],"yoast_head":"\nStudies Show Diabetes Drug Invokana Increases Amputation Risk<\/title>\n<meta name=\"description\" content=\"New studies show that Invokana reduces cardiovascular and kidney complications, but increases amputation risk.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=47350\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alex O\u2019Meara\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=47350\",\"url\":\"https:\/\/asweetlife.org\/?p=47350\",\"name\":\"Studies Show Diabetes Drug Invokana Increases Amputation Risk\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=47350#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=47350#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2014\/12\/Whitepills-Invokana-for-Type-1-diabetes.jpeg\",\"datePublished\":\"2017-07-05T14:46:20+00:00\",\"dateModified\":\"2017-07-05T17:07:08+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/39a63c7215ee072a94bbc4a681de116d\"},\"description\":\"New studies show that Invokana reduces cardiovascular and kidney complications, but increases amputation risk.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=47350#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=47350\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=47350#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2014\/12\/Whitepills-Invokana-for-Type-1-diabetes.jpeg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2014\/12\/Whitepills-Invokana-for-Type-1-diabetes.jpeg\",\"width\":601,\"height\":400,\"caption\":\"Study Shows Diabetes Drug Invokana Increases Amputation Risk\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=47350#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Studies Show Diabetes Drug Invokana Increases Amputation Risk\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/39a63c7215ee072a94bbc4a681de116d\",\"name\":\"Alex O\u2019Meara\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d46cda412d65fd79447ff39275a4856e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d46cda412d65fd79447ff39275a4856e?s=96&d=mm&r=g\",\"caption\":\"Alex O\u2019Meara\"},\"description\":\"Alex was diagnosed with type 1 diabetes 36 years ago. Since then he has run six marathons \u2013 the first when we was 15 \u2013 and the latest a few years ago. In 2006 Alex underwent islet cell transplant and was, for some time, insulin independent. He now lives in Southeastern Arizona where he is working on a novel, teaching college English, pursuing a Master\u2019s degree, and training to run his first 50 mile race.\",\"url\":\"https:\/\/asweetlife.org\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Studies Show Diabetes Drug Invokana Increases Amputation Risk","description":"New studies show that Invokana reduces cardiovascular and kidney complications, but increases amputation risk.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=47350","twitter_misc":{"Written by":"Alex O\u2019Meara","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=47350","url":"https:\/\/asweetlife.org\/?p=47350","name":"Studies Show Diabetes Drug Invokana Increases Amputation Risk","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=47350#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=47350#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2014\/12\/Whitepills-Invokana-for-Type-1-diabetes.jpeg","datePublished":"2017-07-05T14:46:20+00:00","dateModified":"2017-07-05T17:07:08+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/39a63c7215ee072a94bbc4a681de116d"},"description":"New studies show that Invokana reduces cardiovascular and kidney complications, but increases amputation risk.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=47350#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=47350"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=47350#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2014\/12\/Whitepills-Invokana-for-Type-1-diabetes.jpeg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2014\/12\/Whitepills-Invokana-for-Type-1-diabetes.jpeg","width":601,"height":400,"caption":"Study Shows Diabetes Drug Invokana Increases Amputation Risk"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=47350#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Studies Show Diabetes Drug Invokana Increases Amputation Risk"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/39a63c7215ee072a94bbc4a681de116d","name":"Alex O\u2019Meara","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d46cda412d65fd79447ff39275a4856e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d46cda412d65fd79447ff39275a4856e?s=96&d=mm&r=g","caption":"Alex O\u2019Meara"},"description":"Alex was diagnosed with type 1 diabetes 36 years ago. Since then he has run six marathons \u2013 the first when we was 15 \u2013 and the latest a few years ago. In 2006 Alex underwent islet cell transplant and was, for some time, insulin independent. He now lives in Southeastern Arizona where he is working on a novel, teaching college English, pursuing a Master\u2019s degree, and training to run his first 50 mile race.","url":"https:\/\/asweetlife.org\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/47350"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47350"}],"version-history":[{"count":4,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/47350\/revisions"}],"predecessor-version":[{"id":47354,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/47350\/revisions\/47354"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/37306"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}